| Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer KP Olive, MA Jacobetz, CJ Davidson, A Gopinathan, D McIntyre, ... Science 324 (5933), 1457-1461, 2009 | 3525 | 2009 |
| Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia MJ Keating, S O’Brien, M Albitar, S Lerner, W Plunkett, F Giles, M Andreeff, ... Journal of clinical oncology 23 (18), 4079-4088, 2005 | 1317 | 2005 |
| Action of 2′, 2′-difluorodeoxycytidine on DNA synthesis P Huang, S Chubb, LW Hertel, GB Grindey, W Plunkett Cancer research 51 (22), 6110-6117, 1991 | 1157 | 1991 |
| Superoxide dismutase as a target for the selective killing of cancer cells P Huang, L Feng, EA Oldham, MJ Keating, W Plunkett Nature 407 (6802), 390-395, 2000 | 1103 | 2000 |
| Gemcitabine: metabolism, mechanisms of action, and self-potentiation. W Plunkett, P Huang, YZ Xu, V Heinemann, R Grunewald, V Gandhi Seminars in oncology 22 (4 Suppl 11), 3-10, 1995 | 922 | 1995 |
| Comparison of the Cellular Pharmacokinetics and Toxicity of 2′,2′-Difluorodeoxycytidine and 1-β-d-Arabinofuranosylcytosine V Heinemann, LW Hertel, GB Grindey, W Plunkett Cancer research 48 (14), 4024-4031, 1988 | 714 | 1988 |
| Inhibition of mitochondrial respiration: a novel strategy to enhance drug-induced apoptosis in human leukemia cells by a reactive oxygen species-mediated mechanism H Pelicano, L Feng, Y Zhou, JS Carew, EO Hileman, W Plunkett, ... Journal of Biological Chemistry 278 (39), 37832-37839, 2003 | 618 | 2003 |
| Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia PA Thompson, CS Tam, SM O’Brien, WG Wierda, F Stingo, W Plunkett, ... Blood, The Journal of the American Society of Hematology 127 (3), 303-309, 2016 | 615 | 2016 |
| Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma M Tempero, W Plunkett, V Ruiz van Haperen, J Hainsworth, H Hochster, ... Journal of Clinical Oncology 21 (18), 3402-3408, 2003 | 600 | 2003 |
| Fludarabine: a new agent with major activity against chronic lymphocytic leukemia MJ Keating, H Kantarjian, M Talpaz, J Redman, C Koller, B Barlogie, ... | 590 | 1989 |
| Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2', 2'-difluorodeoxycytidine. V Heinemann, YZ Xu, S Chubb, A Sen, LW Hertel, GB Grindey, W Plunkett Molecular pharmacology 38 (4), 567-572, 1990 | 516 | 1990 |
| Gemcitabine: preclinical pharmacology and mechanisms of action. W Plunkett, P Huang, CE Searcy, V Gandhi Seminars in oncology 23 (5 Suppl 10), 3-15, 1996 | 489 | 1996 |
| Ibrutinib and venetoclax for first-line treatment of CLL N Jain, M Keating, P Thompson, A Ferrajoli, J Burger, G Borthakur, ... New England Journal of Medicine 380 (22), 2095-2103, 2019 | 488 | 2019 |
| Mitochondrial respiration defects in cancer cells cause activation of Akt survival pathway through a redox-mediated mechanism H Pelicano, R Xu, M Du, L Feng, R Sasaki, JS Carew, Y Hu, L Ramdas, ... The Journal of cell biology 175 (6), 913-923, 2006 | 463 | 2006 |
| TRIM24 links a non-canonical histone signature to breast cancer WW Tsai, Z Wang, TT Yiu, KC Akdemir, W Xia, S Winter, CY Tsai, X Shi, ... Nature 468 (7326), 927-932, 2010 | 448 | 2010 |
| Cellular elimination of 2′, 2′-difluorodeoxycytidine 5′-triphosphate: a mechanism of self-potentiation V Heinemann, YZ Xu, S Chubb, A Sen, LW Hertel, GB Grindey, W Plunkett Cancer research 52 (3), 533-539, 1992 | 444 | 1992 |
| Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion … AV Kurtova, K Balakrishnan, R Chen, W Ding, S Schnabl, MP Quiroga, ... Blood, The Journal of the American Society of Hematology 114 (20), 4441-4450, 2009 | 426 | 2009 |
| Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. V Gandhi, E Estey, MJ Keating, W Plunkett Journal of Clinical Oncology 11 (1), 116-124, 1993 | 416 | 1993 |
| Free radical stress in chronic lymphocytic leukemia cells and its role in cellular sensitivity to ROS-generating anticancer agents Y Zhou, EO Hileman, W Plunkett, MJ Keating, P Huang Blood, The Journal of the American Society of Hematology 101 (10), 4098-4104, 2003 | 391 | 2003 |
| Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia H Kantarjian, V Gandhi, J Cortes, S Verstovsek, M Du, G Garcia-Manero, ... Blood 102 (7), 2379-2386, 2003 | 375 | 2003 |
